UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 1, 1997, Pages 200-209

  Kim, Perry M ^a   Winn, Louise M ^a   Parman, Toufan ^a   Wells, Peter G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; PHENYTOIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROTECTION; DNA DEGRADATION; DRUG ACTIVATION; DRUG DEGRADATION; DRUG GLUCURONIDATION; DRUG POTENCY; EMBRYOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TERATOGENICITY; TOXICITY TESTING;

ANIMALS; ANTICONVULSANTS; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; EMBRYO; FEMALE; GLUCURONOSYLTRANSFERASE; MALE; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; ORGAN CULTURE TECHNIQUES; OXIDATION-REDUCTION; PHENYTOIN; RATS; RATS, GUNN; RATS, WISTAR;

EID: 0030946410     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. BARCELLONA, P. S., BARALE, R., CAMPANA, A., ZUCCONI, D., ROSSI, V. AND CARANTI, S.: Correlations between embryotoxic and genotoxic effects of phenytoin in mice. Teratogen. Carcinogen. Mutagen. 7: 159-168, 1987.
2. BOSMA, P. J., CHOWDHURY, R. N., GOLDHOORN, B. G., HOFKER, M. H., OUDE ELFERINK, R. P. J., JANSEN, P. L. M. AND CHOWDHURY, J. R.: Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome type I. Hepatology 15: 941-947, 1992.
3. BOSMA, P. J., CHOWDHURY, J. R. AND JANSEN, H. M.: Genetic inheritance of Gilbert's syndrome. Lancet 346: 314-315, 1995.
4. BRIERLY, C. H. AND BURCHELL, B.: Human UDP-glucuronosyl transferases: Chemical defence, jaundice and gene therapy. Bioessays 15: 749-754, 1993.
5. BROWN, L. P., FLINT, O. P., ORTON, T. C. AND GIBSON, G. G.: In vitro metabolism of teratogens by differentiating rat embryo cells. Food Chem. Toxicol. 24: 737-742, 1986.
6. BROWNE, T. R. AND CHANG, T.: Phenytoin biotransformation. In Antiepileptic Drugs, ed. by R. Levy, R. Mattson, B. Meldrum, J. K. Penry and F. E. Dreifuss, 3rd ed., pp. 197-213, Raven Press, New York, 1989.
7. BURCHELL, B., COUGHTRIE, M. W. H. AND JANSEN, P. L. M.: Function and regulation of UDP-glucuronosyltransferase genes in health and liver disease: Report of the Seventh International Workshop on Glucuronidation. September 1993, Pitlochry, Scotland. Hepatology 20: 1622-1630, 1994.
8. BUTLER, T. C.: The metabolic conversion of 5,5-diphenylhydantoin to 5-(p-hydroxyphenyl)-5-phenylhydantoin. J. Pharmacol. Exp. Ther. 119: 1-11, 1957.
9. CHOW, S. A. AND FISCHER, L. J.: Phenytoin metabolism in mice. Drug Metab. Dispos. 10: 156-160, 1982.
10. DE MURAIS, M. F., CHOW, S. Y. M. AND WELLS, P. G.: Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary deficiency in bilirubin UDP-glucuronosyltransferawe. Toxicol. Appl. Pharmacol. 117: 81-87, 1992a.
11. DE MORAIS, M. F., UETRECHT, J. P. AND WELLS, P. G.: Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 102: 577-586, 1992b.
12. DUTTON, G. J.: Acceptor substrates of UDP-glucuronosyltransferase and their assay. In Glucuronidation of Drugs and Other Compounds, ed. by G. J. Dutton, pp. 69-78, CRC Press, Boca Raton, FL, 1980.
13. GUPTA, R. C.: Nonrandom binding of the carcinogen N-hydroxy-2-acetylfluorene to repetitive sequences of rat liver DNA in vivo. Proc. Natl. Acad. Sci. U.S.A. 81: 6943-6947, 1984.
14. HADEBANK, M., ESSER, K. J., BRULL, D., KOTLAREK, F. AND STUMPF, C.: Increased sister chromatid exchange in epileptic children during long-term therapy with phenytoin. Hum. Genet. 81: 71-72, 1982.
15. HANSEN, D. K.: The embryotoxicity of phenytoin: An update on possible mechanisms. Proc. Soc. Exp. Biol. Med. 197: 361-368, 1991.
16. HARBISON, R. D. AND BECKER, B. A.: Comparative embryotoxicity of diphenylhydantoin and some of its metabolites in mice. Teratology 10: 237-242, 1974.
17. HU, Z. AND WELLS, P. G.: In vitro and in vivo biotransformation and covalent binding of benzo[a)pyrene in Gunn and RHA rats with genetic deficiency in bilirubin uridine diphosphate-glucuronosyltransferase. J. Pharmacol. Exp. Ther. 263: 334-342, 1992.
18. HU, Z. AND WELLS, P. G.: Human interindividual variation in lymphocyte UDP-glucuronosyltransferases as a determinant of benzo[a]pyrene covalent binding and cytotoxicity. Proc. Int. Soc. Study Xenobiotics (ISSX) 4: 31, 1993.
19. HU, Z. AND WELLS, P. G.: Modulation of benzo[e]pyrene bioactivation by glucuronidation in lymphocytes and hepatic microsomes from rats with a hereditary deficiency in bilirubin UDP-glucuronosyltransferases. Toxicol. Appl. Pharmacol. 127: 306-313, 1994.
20. HUNKE, M. H. AND CARPENTER, N. J.: Effects of diphenylhydantoin on the frequency of sister chromatid exchange in human lymphocytes. Am. J. Hum. Genet. 30: 83A, 1978.
21. IYANAGI, T.: Molecular basis of multiple UDP-glucuronoayltranaferase isoenzyme deficiencies in the hyperbilirubinemic rat (Gunn rat). J. Biol. Chem. 266: 24048-24052, 1991.
22. JUCHAU, M. R., LEE, Q. P. AND FANTEL, A. G.: Xenobiotic biotranaformation/ bioactivation in organogenesis-stage conceptual tissues: Implications for embryotoxicity and teratogenesis. Drug Metab. Rev. 24: 195-238, 1992.
23. KIM, P. M. AND WELLS, P. M.: Mechanism of benzo[a]pyrene (B[a]P)-induced micronucleus formation in cultured skin fibroblasts from Wistar rats. Toxicologist 14: 223, 1994.
24. KIM, P. M. AND WELLS, P. M.: Evidence for cytochrome P4501A1- and prostaglandin H synthase-dependent DNA oxidation in the mechanism of benzo[a]pyrene-initiated micronucleus formation in cultured Wistar rat skin fibroblasts. Proc. Am. Assoc. Cancer Res. 36: 600, 1995.
25. KIM, P. M. AND WELLS, P. M.: Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyndyl)-1-butanone and benzo[a]pyrene. Cancer Res. 56: 1526-1532, 1996a.
26. KIM, P. M. AND WELLS, P. M.: Phenytoin-initiated hydroxyl radical formation: Characterization by enhanced salicylate hydroxylation. Mol. Pharmacul. 49: 172-181, 1996b.
27. LAPOSA, R. R., CHAN, C. K., WILEY, M. J. AND WELLS, P. G.: Enhanced phenytoin embryoputhy in p53-deficient mice: Characterisation of embryonic p53 genotype and the p53. p21 and Bax DNA damage response proteins. Fundam. Appl. Toxicol. 30: suppl. 1, 195, 1996.
28. LEONARD, A., DE MEESTER, C., FABRY, F., DE SAINT-GEORGES, L. AND DUMONT, P.: Lack of mutagenicity of diphenylhydantoin in in viro short-term tests. Mutat. Res. 137: 79-88, 1984.
29. MOGHRABI, N., SUTERLAND, L., WOOSTER, R., POVEY, S., BOXER, M. AND BURCHELL, B.: Chromosomal assignment of human phenol and bilirubin UDP-glucuronosyltransferase gene (UGT1A-subfamily). Ann. Hum. Genet. 56: 81-91, 1992.
30. MOGHRABI, N., SUTHERLAND, L., WOOSTER, R., POVEY, S., BOXER, M. AND BURCHELL, B.: Cosegregation of intragenic markers with a novel mutation that causes Crigler-Najjar syndrome type I: Implications in carrier detection and prenatal diagnosis. Am. J. Hum. Genet. 53: 722-729, 1993a.
31. MOGHRABI N., SUTHERLAND, L., WOOSTER, R., POVEY S., BOXER, M. AND BURCHELL, B.: Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2. Genomics 18: 171-173, 1993b.
32. MONAGHAN, G., POVEY, S., BURCHELL, B. AND BOXER, M.: Localisation of bile acid UDP-glucuronosyltransferase gene (UGT2B) to chromosome 4 using the polymerase chain reaction. Genomics 13: 908-909, 1992.
33. MONAGHAN, G., RYAN, M., SEDDON, R., HUME, R. AND BURCHELL, B.: Genetic variation in UDP-glucuronosyltransferase gene promotor and Gilbert's syndrome. Lancet 347: 578-581, 1996.
34. MONTES DE OCA-LUNA, R., LEAL-GARZA, C. H., BACA-SEVILLA, S. AND GARZA-CHPA, R.: The effect of diphenylhydantoin on the frequency of micronuclei in bone-marrow polychromatic erythrocytes of mice. Mutat. Res. 141: 183-187, 1984.
35. NEW, D. A. T.: Whole embryo culture and the study of mammalian embryos during organogenesis. Biol. Rev. 53: 81-122, 1978.
36. NICOL, C. J., HARRISON, M. L., LAPOSA, R. R., GIMELSHTEIN, I. L. AND WELLS, P. G.: A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nature Genet. 10: 181-187, 1995.
37. ODELL, G. B. AND GUILDS, B.: Hereditary hyporbilirubinemias. Prog. Med. Genet. 4: 103-134, 1980.
38. PARMAN, T., CHEN, G., BRAY, T. M. AND WELLS, P. G.: Bioactivation of phenytoin, thalidomicle and related teratogens to a free radical intermediate using prostaglandin H synthase (PHS) or hepatic microsomes: Characterisation by electron spin resonance (ESR) spectrometry. Fundam. Appl. Toxicol. 30: suppl. 1, 246, 1996.
39. PORTER, J. R.: How to use antiepileptic drugs. In Antiepileptic Drugs, ed. by R. Levy, R. Mattson, B. Meldrum, J. K. Penry and F. E. Dreifuas, 3rd ed., pp. 117-131, Raven Press, New York, 1989.
40. SEZZANO, P., RAIMONDI, A., ARBOIX, M. AND PANTAROTTO, C.: Mutagenicity of diphenylhydantoin and some of its metabolites towards Salmonella typhimuriurn strains. Mutat. Res. 103: 219-228, 1982.
41. SHIGENAGA, M. K. AND AMES, B. N.: Assays for 8-hydroxy-2′-deoxyguanosine: A biomarker of in vivo oxidativc DNA damage. Free Radicals Biol. Med. 10: 211-216, 1991.
42. SMITH, B. J., CURTIS, J. F. AND ELING, T. E.: Bioactivation of xenobiotics by prostaglandin H synthase. Chem.-Biol. Interact. 79: 245-264, 1991.
43. SMITH, R. G., DAVES, G. D., LYNN, R. K. AND GERBER, N.: Hydantoin ring glucuronidation: Characterization of a new metabolite of 5,5-diphenylhydantoin in man and the rat. Biomed. Maws Spectrom. 4: 275-279, 1977.
44. VIENNEAU, D. S., DEBONI, U. AND WELLS, P. G.: Potential genoprotective role for UDP-glucuronosyltransferases in chemical carcinogenesis: Initiation of micronuclei by benzo[a]pyrene and benzo[e]pyrene in UDP-glucuronosyltransferase-deficient cultured rat skin fibroblasts. Cancer Res. 55: 1046-1051, 1995.
45. 14C]phenytoin in the rat. J. Pharmacol. Exp. Ther. 208: 257-262, 1979.
46. WELLS, P. G., OBILIO, F. C. AND DE MORAIS, S. M. F.: Benzo[a]pyrene embryopathy in rats genetically deficient in bilirubin UDP-glucuronyltransferase. FASEB J. 3: A1025, 1989.
47. WELLS, P. G. AND KIM, P. M.: UDP-Glucuronosyltransferase (UGT)-medinted genoprotection in phenytoin- and 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH)-initiated DNA oxidation and micronucleus formation. Fundam. Appl. Toxicol. 30: suppl. 1, 234, 1996.
48. WELLS, P. G. AND WINN, L. M.: Biochemical toxicology of chemical teratogenesis. Crit. Rev. Biochem. Mol. Biol. 31: 1-40, 1996.
49. WINN, L. M. AND WELLS, P. G.: Free radical-mediated mechanisms of anticonvulsant teratogenicity. Eur. J. Neurol. 2: Suppl. 4, 5-29, 1995a.
50. WINN, L. M. AND WELLS, P. G.; Phenytoin-initiated DNA oxidation in murine embryo culture, and embryoprotection by the antioxidative enzymes super-oxide dismutase and catalase: Evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol. 48: 112-120, 1995b.